Assuntos
Indústria Farmacêutica/tendências , Necessidades e Demandas de Serviços de Saúde/tendências , Testes Imunológicos/tendências , Medicina de Precisão/tendências , Análise Custo-Benefício/tendências , Indústria Farmacêutica/economia , Previsões , Alemanha , Necessidades e Demandas de Serviços de Saúde/economia , Testes Imunológicos/economia , Medicina de Precisão/economiaRESUMO
The management of tissues and cellular samples by the pathologists in the infectious and tropical diseases pathology field in 2014 needs a strong knowledge of both morphological and molecular domains which includes the good control: (i) of the taxonomy of infectious and tropical diseases pathology leading to the pathogens identification and (ii) of the ancillary methods which can be used in fixed samples in order to detect or better identify these pathogens. There is a recent paradox in France concerning the frequency of infectious diseases to be diagnosed in pathology laboratories and the progressive loss of pathologist's expertise in this domain. Different reasons could explain this statement including the omnipresence of the tumour lesions to be managed in a pathology laboratory as well as the recent constraints associated with the different biomarkers that are mandatory to be detected by immunohistochemistry and/or by molecular biology. Even if the microbiologists play a pivotal role for identifying the different pathogens as well as for the assessment of their sensitivity to the anti-microbial drugs, a large number of infectious diseases can be diagnosed only on fixed tissue and/or cells by the pathologists. The purpose of this review is to describe the current and future issues of infectious and tropical diseases diagnoses in pathology laboratories, in particular in France.
Assuntos
Infecções/patologia , Infectologia/organização & administração , Patologia Clínica/tendências , Medicina Tropical/organização & administração , Técnicas de Laboratório Clínico/métodos , Técnicas de Laboratório Clínico/tendências , Doenças Transmissíveis Emergentes/epidemiologia , Doenças Transmissíveis Emergentes/patologia , França/epidemiologia , Hospitais Especializados/organização & administração , Humanos , Testes Imunológicos/tendências , Infecções/epidemiologia , Infectologia/educação , Infectologia/métodos , Relações Interprofissionais , Oncologia/métodos , Oncologia/tendências , Técnicas Microbiológicas/tendências , Patologia Clínica/educação , Patologia Clínica/métodos , Patologia Clínica/organização & administração , Competência Profissional , Apoio à Pesquisa como Assunto , Telemedicina/organização & administração , Telemedicina/tendências , Medicina Tropical/educação , Medicina Tropical/métodosRESUMO
Vaccinomics aims to integrate variability information from multiple levels of the biological hierarchy from genome to proteome to metabolome, and ways in which these biological parts interact with each other and the environment. Vaccinomics holds significant promise as a new public health tool in designing safer and more effective vaccines for both developed and developing countries. Vaccinomics tests that are envisioned to be used in tandem with vaccine-based health interventions could permit an informed forecast of individual and subpopulation variations in immune responses to vaccines, reduce adverse effects, and contribute to a foundation for rational and directed use of vaccines. A proactive, multidisciplinary engagement with vaccinomics is now timely and much needed in order to develop regulations that best ensure the protection of the public and promote the transition of vaccinomics innovations from discovery to real-life public health applications. This article examines and compares the regulatory oversight of vaccinomics tests in Canada, the United States, and Europe. Recent trends in these jurisdictions suggest that regulatory agencies view personalized genomics/omics medicine, such as vaccinomics, as a desirable goal. At the same time, proposals to increase oversight could impact progress in the field and affect the availability of vaccinomics tests in public health practice and the diagnostic test market. The comparative analysis of vaccinomics in three jurisdictions presented in this article highlights both the convergence and divergence of regulatory oversight. In a rapidly emerging field such as vaccinomics that is pivotal for global public health, achieving better harmonization of policies may be an advantageous target, while ensuring that symmetry exists between the goals of public safety and promoting public health innovation. We suggest it is now timely to proactively initiate a constructive dialogue among all stakeholders (publics, policymakers, researchers, private sector, governments) to foster the development of appropriately targeted regulatory policies in this field.
Assuntos
Medicina Preventiva/organização & administração , Vacinas/imunologia , Canadá , Ensaios Clínicos como Assunto , Europa (Continente) , Genômica , Humanos , Testes Imunológicos/tendências , Farmacogenética , Medicina de Precisão , Medicina Preventiva/economia , Medicina Preventiva/legislação & jurisprudência , Estados UnidosRESUMO
Based on the tuberculin skin test it is estimated that latent tuberculosis infection is present in one-third of the world's population. The new strategies in public health and research are aimed to reduce and eradicate this enormous reservoir. However, the absence of effective biomarkers for diagnosis and treatment of latent tuberculosis limits the development of new drugs and vaccines. Some components are present in both, the PPD (used in the tuberculin skin test) and the BCG vaccine. This increases the number of false positives in vaccinated individuals. Nowadays, there is not an immune diagnostic method that can differentiate latent tuberculosis and tuberculosis disease. New studies have addressed some strategies including specific antibodies, new cytokines and / or antigens as candidates for biomarkers. However, the high costs of these studies, the low number of participants and their different methodology make difficult a future meta-analysis and more conclusive results.
Assuntos
Testes Imunológicos/métodos , Tuberculose/diagnóstico , Adulto , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/sangue , Biomarcadores , Criança , Diagnóstico Diferencial , Saúde Global , Humanos , Testes Imunológicos/economia , Testes Imunológicos/tendências , Recém-Nascido , Interferon gama/sangue , Tuberculose Latente/diagnóstico , Tuberculose Latente/epidemiologia , Tuberculose Latente/imunologia , Mycobacterium tuberculosis/imunologia , Mycobacterium tuberculosis/isolamento & purificação , Fatores de Risco , Escarro/microbiologia , Teste Tuberculínico , Tuberculose/epidemiologia , Tuberculose/imunologiaRESUMO
Tuberculosis (TB) still represents a monumental problem, with more than two million deaths every year worldwide. The current diagnostics for TB offer sub-optimal accuracy both for the active and the latent form of infection and are often based on technologies unaffordable in low-income settings. The tuberculin skin test was the first diagnostic based on an acquired immune response towards Mycobacterium tuberculosis (MTB). Advances in molecular and cellular biology and the elucidation of the mechanisms governing the relation between MTB and the human immune system form the basis for new and more accurate assays, potentially able to fill the gaps and limits of classical diagnostics. However, the process of validating new tests is still complex and hampered by specific questions regarding TB immunology and natural history. We present here a summary of the current approaches to validate new diagnostics based on the detection of immunological biomarkers of TB infection.
Assuntos
Testes Imunológicos/tendências , Mycobacterium tuberculosis/imunologia , Tuberculose Pulmonar/diagnóstico , Imunidade Adaptativa , Animais , Biomarcadores/metabolismo , Humanos , Tuberculose Pulmonar/economia , Tuberculose Pulmonar/imunologia , Estudos de Validação como AssuntoRESUMO
In this article information on the main immunobiological preparations, including vaccines and toxoids, phages, eubiotics, preparations obtained on the basis of antibodies, immunomodulators, new adaptogens of different origin, is presented. The problem of the development of new diagnostic preparations and biosensors whose action is based on specific immunological reactions is discussed. The expected use of more effective, more natural, as well as free from many drawbacks, modern immunobiological preparations in the medical practice of the XXI century is emphasized.